Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.60 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464733 | 0.90 | SRD5A2 (0.81) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6087478 | 0.90 | SRD5A2 (0.81) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5507380 | 0.88 | SRD5A2 (0.78) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4023414 | 0.88 | SRD5A2 (0.78) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL8687408 | 0.87 | SRD5A2 (0.76) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13802531 | 0.85 | SRD5A2 (0.74) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL700511 | 0.85 | SRD5A2 (0.73) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5509218 | 0.85 | SRD5A2 (0.73) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5507214 | 0.84 | SRD5A2 (0.71) | SRD5A2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13802519 | 0.84 | SRD5A2 (0.72) | SRD5A2MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-7531668-B2 | 2-arylcarboxamide-nitrogenous heterocycle compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MSD K.K. (JP) | 2007-12-27 | — | — | US | disclosed |
| CN-101065356-A | 2-arylcarboxamide-nitrogen-containing heterocyclic compounds | BANYU PHARMA CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| EP-1798221-A1 | 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-5852046-A | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0639573-A1 | Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, FFAR1 | SRD5A2 286/4885MEN1 2914/4885NPC1 583/4885 |
| US-20070299070-A1 | 2-Arylcarboxamide-Nitrogenous Heterocycle Compound | MCHR2, MCHR1, NPY2R | SRD5A2 430/4885MEN1 921/4885NPC1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.